By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Upper respiratory combinations > Phenylephrine and promethazine > Phenylephrine / Promethazine Dosage
Upper respiratory combinations
https://themeditary.com/dosage-information/phenylephrine-promethazine-dosage-8849.html

Phenylephrine / Promethazine Dosage

Drug Detail:Phenylephrine and promethazine (Phenylephrine and promethazine [ fen-ill-eff-rin-and-pro-meh-thah-zeen ])

Drug Class: Upper respiratory combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Allergic Rhinitis

5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

Comments:

  • Each 5 mL contains promethazine 6.25 mg and phenylephrine 5 mg.

Use: For the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Usual Adult Dose for Cold Symptoms

5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

Comments:

  • Each 5 mL contains promethazine 6.25 mg and phenylephrine 5 mg.

Use: For the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Usual Pediatric Dose for Allergic Rhinitis

Less than 2 years: Contraindicated

2 years to less than 6 years: 1.25 to 2.5 mL orally every 4 to 6 hours
Maximum dose: 15 mL in 24 hours (promethazine 18.75 mg; phenylephrine 15 mg)

6 years to less than 12 years: 2.5 to 5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

12 years to 18 years: 5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

Comments:

  • Each 5 mL contains promethazine 6.25 mg and phenylephrine 5 mg.
  • Extra caution is advised with use of promethazine in children as respiratory depression is strongly associated with use; however, its occurrence is not directly related to individualized weight base dosing.

Use: For the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Usual Pediatric Dose for Cold Symptoms

Less than 2 years: Contraindicated

2 years to less than 6 years: 1.25 to 2.5 mL orally every 4 to 6 hours
Maximum dose: 15 mL in 24 hours (promethazine 18.75 mg; phenylephrine 15 mg)

6 years to less than 12 years: 2.5 to 5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

12 years to 18 years: 5 mL orally every 4 to 6 hours
Maximum dose: 30 mL in 24 hours (promethazine 37.5 mg; phenylephrine 30 mg)

Comments:

  • Each 5 mL contains promethazine 6.25 mg and phenylephrine 5 mg.
  • Extra caution is advised with use of promethazine in children as respiratory depression is strongly associated with use; however, its occurrence is not directly related to individualized weight base dosing.

Use: For the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Use with caution

Dose Adjustments

Elderly: Dose selection should be cautious, usually starting the low end of the dosing range.

Precautions

US BOXED WARNING: POTENTIALLY FATAL RESPIRATORY DEPRESSION IN CHILDREN LESS THAN 2 YEARS OF AGE:

  • Promethazine should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. In postmarketing cases of respiratory depression, which have included fatalities, a wide range of weight-based doses have resulted in respiratory depression in these patients.
  • Caution should be exercised when administering promethazine to pediatric patients 2 years of age and older. It is recommended that the lowest effective dose of promethazine be used and concomitant administration of other drugs with respiratory depressant effects be avoided.

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally as directed; do not exceed recommended doses
  • Use calibrated measuring devices; a household spoon is not an accurate measuring device

Storage requirements:
  • Protect from light; keep tightly closed
  • Store at 20C to 25C (68F to 77F)

General:
  • A wide range of promethazine weight-based doses have resulted in respiratory depression in pediatric patients; administration with other respiratory depressants has been associated with respiratory depression and sometimes death in pediatric patients.
  • An increased susceptibility to dystonia has been observed in children who are acutely ill and also dehydrated.
  • Hallucinations and convulsions have occurred with therapeutic doses of promethazine in pediatric patients.

Monitoring:
  • Monitor for excessive sedation
  • Monitor for respiratory depression
  • Monitor for involuntary movements

Patient advice:
  • Patients should be advised this drug may cause marked drowsiness and impair the mental and/or physical abilities required for driving or operating machinery; concomitant use of alcohol and other CNS depressants should be avoided.
  • Patients should be instructed to report any involuntary muscle movements.
  • Patients should be instructed to avoid prolonged sun exposure.
  • Patients should be made aware that fatal respiratory depression has occurred in pediatric patients and use in pediatric patients should be undertaken with extreme caution.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by